GlaxoSmithKline: Crohn Disease trials
The registry lists 13 Crohn Disease studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 4 have results posted.
Phase 1 6Phase 2 2Phase 3 4No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's DiseaseTerminatedNCT01536418Phase 3Results posted
- Open-Label Extension Study of GSK1605786ATerminatedNCT01318993Phase 3Results posted
- GSK1605786A in the Maintenance of Remission in Subjects With Crohn's DiseaseTerminatedNCT01316939Phase 3Results posted
- A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's DiseaseCompletedNCT01277666Phase 3Results posted
- A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy ParticipantsActive, not recruitingNCT06681181Phase 1
- Retrospective Analysis of Systemic Glucocorticoid Mediated Long-term Effects, Patient Pathways and Economic Burden Across Multiple IndicationsCompletedNCT06488703
- Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's DiseaseWithdrawnNCT04151225Phase 2
- Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese SubjectsCompletedNCT01827631Phase 1
- Japanese Phase I of GSK1605786CompletedNCT01611805Phase 1
- A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult SubjectsCompletedNCT01489943Phase 1
- A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy SubjectsCompletedNCT01114607Phase 1
- PBMC (Peripheral Blood Mononuclear Cells) /Lymphocyte SPECT (Single Photon Emission Computerized Tomography) Imaging in Crohn's DiseaseCompletedNCT01051622Phase 1
- Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's DiseaseCompletedNCT00101946Phase 2